EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer

Andrej Zivanovic, Jeffrey T Miller, Sarah A Munro, Todd P Knutson, Yingming Li, Courtney N Passow, Pijus Simonaitis, Molly Lynch, LeAnn Oseth, Shuang G Zhao, Felix Y Feng, Pernilla Wikström und 5 weitere

NAR Cancer · 09.06.2023 · 5 (3)

DOI: 10.1093/narcan/zcad045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NAR Cancer, online erschienen am 24.08.2023. Verfasst von Andrej Zivanovic und 16 weiteren Autor:innen. Beteiligte Einrichtung: Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Androgen receptor (AR) inhibition is standard of care for advanced prostate cancer (PC). However, efficacy is limited by progression to castration-resistant PC (CRPC), usually due to AR re-activation via mechanisms that include AR amplification and structural rearrangement. These two classes of AR alterations often co-occur in CRPC tumors, but it is unclear whether this reflects intercellular or intracellular heterogeneity of AR. Resolving this is important for developing new therapies and predictive biomarkers. Here, we analyzed 41 CRPC tumors and 6 patient-derived xenografts (PDXs) using linked-read DNA-sequencing, and identified 7 tumors that developed complex, multiply-rearranged AR gene structures in conjunction with very high AR copy number. Analysis of PDX models by optical genome mapping and fluorescence in situ hybridization showed that AR residing on extrachromosomal DNA (ecDNA) was an underlying mechanism, and was associated with elevated levels and diversity of AR expression. This study identifies co-evolution of AR gene copy number and structural complexity via ecDNA as a mechanism associated with endocrine therapy resistance.

Autor:innen und Institutionen

  • Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
  • Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN, USA.
  • University of Minnesota Genomics Center, University of Minnesota, Minneapolis, MN, USA.
  • Department of Computer Science, Princeton University, Princeton, NJ, USA.
  • Department of Human Oncology, University of Wisconsin-Madison, Madison, WI, USA.
  • Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.

ORCID-Profile: Scott M Dehm

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Zivanovic, A., Miller, J. T., Munro, S. A., Knutson, T. P., Li, Y., Passow, C. N., Simonaitis, P., Lynch, M., Oseth, L., Zhao, S. G., Feng, F. Y., Wikström, P., Corey, E., Morrissey, C., Henzler, C., Raphael, B. J., & Dehm, S. M. (2023). Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer. NAR Cancer, 5(3). https://doi.org/10.1093/narcan/zcad045

Vancouver

Zivanovic A, Miller JT, Munro SA, Knutson TP, Li Y, Passow CN, et al. Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer. NAR Cancer. 2023;5(3). doi:10.1093/narcan/zcad045

BibTeX
@article{Zivanovic2023,
  author = {Zivanovic, Andrej and Miller, Jeffrey T and Munro, Sarah A and Knutson, Todd P and Li, Yingming and Passow, Courtney N and Simonaitis, Pijus and Lynch, Molly and Oseth, LeAnn and Zhao, Shuang G and Feng, Felix Y and Wikström, Pernilla and Corey, Eva and Morrissey, Colm and Henzler, Christine and Raphael, Benjamin J and Dehm, Scott M},
  title = {Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer},
  journal = {NAR Cancer},
  year = {2023},
  volume = {5},
  number = {3},
  doi = {10.1093/narcan/zcad045}
}
Kostenlos starten →